Condition: Malignant Neoplasm · Carcinoma, Merkel Cell · Lymphoma · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for new ways to treat people with solid tumors, lymphomas (blood cancers), and a certain type of skin cancer. The goals of this study are to learn: * About the safety of pembrolizumab (the study medicine) and if people tolerate it * What happens to different doses of pembrolizumab in a person's body over time * How the cancer responds (gets smaller or goes away) to treatment
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Nagoya City University Hospital ( Site 0003) | Nagoya, Aichi-ken, Japan | Recruiting |
| Nagoya City University Hospital ( Site 0007) | Nagoya, Aichi-ken, Japan | Recruiting |
| Sapporo Hokuyu Hospital ( Site 0005) | Sapporo, Hokkaido, Japan | Recruiting |
| Hyogo Prefectural Kobe Children's Hospital ( Site 0006) | Kobe, Hyōgo, Japan | Recruiting |
| National Cancer Center Hospital ( Site 0002) | Chūō, Tokyo, Japan | Recruiting |
| National Hospital Organization Kyushu Cancer Center ( Site 0001) | Fukuoka, Japan | Recruiting |
| University Hospital,Kyoto Prefectural University of Medicine ( Site 0004) | Kyoto, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07302347